Search
Now showing items 1-6 of 6
Design and synthesis of dual kinase-bromodomain inhibitors targeting ALK and BRD4
(Institute of Cancer Research (University Of London), 2019-12-31)
Neuroblastoma is a paediatric cancer of neural crest origin and is the most common extracranial tumour in childhood. In high-risk patients with poor clinical outcome, mutations within the kinase domain of anaplastic lymphoma ...
Modulation of the tumour immune microenvironment by cancer-associated fibroblasts
(Institute of Cancer Research (University Of London), 2019-11-30)
The breast tumour microenvironment (TME) consists of a variety of non-cancerous cell types that can promote or inhibit cancer progression. Cancer-associated fibroblasts (CAFs) represent a major component of the breast TME ...
A translational study in pancreatic neuroendocrine neoplasms
(Institute of Cancer Research (University Of London), 2019-11-30)
Pancreatic neuroendocrine neoplasms (PanNENs) are rare, highly heterogeneous tumours. There have been significant recent advances in our knowledge of genomic events underlying their pathogenesis. However, treatment decisions ...
Structural and functional characterization of the human and yeast TFIIIC complex
(Institute of Cancer Research (University Of London), 2019-11-30)
TFIIIC is one of the conserved transcription factors required for RNA Polymerase (Pol) III transcription, which transcribes DNA into untranslated RNAs, such as tRNAs. However, TFIIIC's mechanistic role in Pol III regulation ...
Novel concepts for automated segmentation to facilitate MRI-guided radiotherapy in head and neck cancer
(Institute of Cancer Research (University Of London), 2019-09-30)
The dramatic increase of magnetic resonance imaging (MRI) in daily treatment planning and response assessment of radiotherapy (RT) requires the development of reliable auto-segmentation algorithms for organs-at-risk (OARs) ...
Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer
(Institute of Cancer Research (University Of London), 2019-12-31)
KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ...